Company Overview of Human Genome Sciences Inc.
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The company’s mid- and early-stage pipeline products comprise Mapatumumab, a human monoclonal antibody for the treatment of advanced hepatocellular cancer; HGS1036, a biologic for multiple cancers; HGS1029, an IAP inhibitor that is in Phase 1 development to treat patients with solid and lymphoid tumors; and HGS1025, a human monoclonal antibody to the CCR5 receptor that would have entered Phase 1b development in ulcerative colitis. It also holds financial rights to certain products in the Gla...
14200 Shady Grove Road
Rockville, MD 20850-7464
Founded in 1992
Key Executives for Human Genome Sciences Inc.
Chief Executive, President and Director
Chief Financial Officer and Director
Senior Vice President of Operations
Executive Vice President, Secretary and General Counsel
Executive Vice President of Research & Development
Compensation as of Fiscal Year 2014.
Human Genome Sciences Inc. Key Developments
GSK Reportedly To Acquire Human Genome
Jun 23 14
GlaxoSmithKline plc (LSE:GSK) is reportedly expected to announce an agreement to acquire Human Genome Sciences Inc. for about $2.8 billion. GlaxoSmithKline is expected to pay around $14 per share.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries